Unknown

Dataset Information

0

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.


ABSTRACT:

Purpose

Increasing tumor-infiltrating lymphocytes (TIL) is associated with higher rates of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in patients with triple-negative breast cancer (TNBC). However, the presence of TILs does not consistently predict pCR, therefore, the current study was undertaken to more fully characterize the immune cell response and its association with pCR.

Experimental design

We obtained pretreatment core-needle biopsies from 105 patients with stage I-III TNBC enrolled in ARTEMIS (NCT02276443) who received NAT from Oct 22, 2015 through July 24, 2018. The tumor-immune microenvironment was comprehensively profiled by performing T-cell receptor (TCR) sequencing, programmed death-ligand 1 (PD-L1) IHC, multiplex immunofluorescence, and RNA sequencing on pretreatment tumor samples. The primary endpoint was pathologic response to NAT.

Results

The pCR rate was 40% (42/105). Higher TCR clonality (median = 0.2 vs. 0.1, P = 0.03), PD-L1 positivity (OR: 2.91, P = 0.020), higher CD3+:CD68+ ratio (median = 14.70 vs. 8.20, P = 0.0128), and closer spatial proximity of T cells to tumor cells (median = 19.26 vs. 21.94 μm, P = 0.0169) were associated with pCR. In a multivariable model, closer spatial proximity of T cells to tumor cells and PD-L1 expression enhanced prediction of pCR when considered in conjunction with clinical stage.

Conclusions

In patients receiving NAT for TNBC, deep immune profiling through detailed phenotypic characterization and spatial analysis can improve prediction of pCR in patients receiving NAT for TNBC when considered with traditional clinical parameters.

SUBMITTER: Yam C 

PROVIDER: S-EPMC8752638 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.

Yam Clinton C   Yen Er-Yen EY   Chang Jeffrey T JT   Bassett Roland L RL   Alatrash Gheath G   Garber Haven H   Huo Lei L   Yang Fei F   Philips Anne V AV   Ding Qing-Qing QQ   Lim Bora B   Ueno Naoto T NT   Kannan Kasthuri K   Sun Xiangjie X   Sun Baohua B   Parra Cuentas Edwin Roger ER   Symmans William Fraser WF   White Jason B JB   Ravenberg Elizabeth E   Seth Sahil S   Guerriero Jennifer L JL   Rauch Gaiane M GM   Damodaran Senthil S   Litton Jennifer K JK   Wargo Jennifer A JA   Hortobagyi Gabriel N GN   Futreal Andrew A   Wistuba Ignacio I II   Sun Ryan R   Moulder Stacy L SL   Mittendorf Elizabeth A EA  

Clinical cancer research : an official journal of the American Association for Cancer Research 20211001 19


<h4>Purpose</h4>Increasing tumor-infiltrating lymphocytes (TIL) is associated with higher rates of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in patients with triple-negative breast cancer (TNBC). However, the presence of TILs does not consistently predict pCR, therefore, the current study was undertaken to more fully characterize the immune cell response and its association with pCR.<h4>Experimental design</h4>We obtained pretreatment core-needle biopsies from 105 patients  ...[more]

Similar Datasets

| S-EPMC7565153 | biostudies-literature
| S-EPMC3747378 | biostudies-literature
| S-EPMC7534548 | biostudies-literature
| S-EPMC10137141 | biostudies-literature
| S-EPMC10871101 | biostudies-literature
| S-EPMC5865448 | biostudies-literature
| S-EPMC9243491 | biostudies-literature
| S-EPMC3813597 | biostudies-literature
| S-EPMC5053310 | biostudies-literature
| S-EPMC5995183 | biostudies-literature